Frequency, phenotype, outcome and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disea…

Background: The monoclonal anti-tumor necrosis factor (TNF) antibody adalimumab has recently been approved for Crohn's disease (CD) and evaluated for ulcerative colitis (UC). Cutaneous lesions associated with its administration have not been prospectively studied in inflammatory bowel disease (IBD). Methods: We evaluated the first fifty consecutive patients (female n=30, median age 32½ years [IQR 27–46]) with CD (n=46) and UC (n=4) who received adalimumab (82% induction with 160/80 and 94% maintenance with 40mg s.c. biweekly) at our center and were followed-up for a median of 17 months [IQR 12–21]. The Kaplan-Me…